MX376835B - Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos. - Google Patents

Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos.

Info

Publication number
MX376835B
MX376835B MX2017011269A MX2017011269A MX376835B MX 376835 B MX376835 B MX 376835B MX 2017011269 A MX2017011269 A MX 2017011269A MX 2017011269 A MX2017011269 A MX 2017011269A MX 376835 B MX376835 B MX 376835B
Authority
MX
Mexico
Prior art keywords
inhibitors
lysyl oxidase
oxidase type
compounds
fluorinated
Prior art date
Application number
MX2017011269A
Other languages
English (en)
Spanish (es)
Other versions
MX2017011269A (es
Inventor
Imelda Calderon
John Howard Hutchinson
Martin W Rowbottom
Original Assignee
Pharmakea Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmakea Inc filed Critical Pharmakea Inc
Publication of MX2017011269A publication Critical patent/MX2017011269A/es
Publication of MX376835B publication Critical patent/MX376835B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2017011269A 2015-03-06 2016-03-03 Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos. MX376835B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562129543P 2015-03-06 2015-03-06
PCT/US2016/020732 WO2016144703A1 (en) 2015-03-06 2016-03-03 Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
MX2017011269A MX2017011269A (es) 2018-01-12
MX376835B true MX376835B (es) 2025-03-07

Family

ID=56879638

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011269A MX376835B (es) 2015-03-06 2016-03-03 Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos.

Country Status (15)

Country Link
US (3) US10150732B2 (enExample)
EP (2) EP3795568A1 (enExample)
JP (1) JP6697809B2 (enExample)
KR (1) KR102594441B1 (enExample)
CN (1) CN107592861B (enExample)
AU (2) AU2016229268B2 (enExample)
BR (1) BR112017019150B1 (enExample)
CA (1) CA2977947A1 (enExample)
EA (1) EA034891B1 (enExample)
ES (1) ES2838977T3 (enExample)
IL (1) IL254236A0 (enExample)
MX (1) MX376835B (enExample)
PH (1) PH12017501611A1 (enExample)
SG (1) SG11201707246YA (enExample)
WO (1) WO2016144703A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6800872B2 (ja) * 2015-03-06 2020-12-16 ファーマケア，インク． リシルオキシダーゼ様２阻害剤とその使用
EP3795568A1 (en) 2015-03-06 2021-03-24 Pharmakea, Inc. Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
GB201602934D0 (en) 2016-02-19 2016-04-06 Cancer Res Inst Royal Compounds
US20190192697A1 (en) * 2016-09-07 2019-06-27 Pharmakea, Inc. Chemical probes of lysyl oxidask-like 2 and uses thereof
JP7079772B2 (ja) * 2016-09-07 2022-06-02 ファーマケア，インク． リシルオキシダーゼ様２阻害剤の結晶形態および製造方法
MA46203A (fr) * 2016-09-07 2019-07-17 Pharmakea Inc Utilisations d'un inhibiteur d'homologue 2 de lysyl-oxydase
EP3597040A4 (en) * 2017-03-17 2020-12-09 Meiji Seika Pharma Co., Ltd. PLANT DISEASE CONTROL AGENT
WO2019112968A1 (en) 2017-12-05 2019-06-13 Peng Wang Processes to produce elagolix
CN110128355A (zh) * 2018-01-17 2019-08-16 苏州鹏旭医药科技有限公司 一种含有6-甲基尿嘧啶结构化合物的制备方法
PE20211001A1 (es) 2018-02-27 2021-06-01 Incyte Corp Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
MA52940A (fr) 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
GB201809295D0 (en) 2018-06-06 2018-07-25 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
GEP20237560B (en) 2018-07-05 2023-10-25 Incyte Corp Fused pyrazine derivatives as a2a / a2b inhibitors
US12178791B2 (en) * 2018-08-03 2024-12-31 Syntara Limited Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof
GB201818750D0 (en) 2018-11-16 2019-01-02 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
BR112022000782A2 (pt) * 2019-07-25 2022-03-15 Pharmaxis Ltd Composto, composição farmacêutica, processo para preparar um composto, composto intermediário, e, uso de um composto, ou de um sal farmaceuticamente aceitável ou solvato do mesmo, ou de uma composição farmacêutica
MX2022005388A (es) 2019-11-06 2022-05-24 Yuhan Corp Compuestos de pirrolidina y piperidina.
US20230310445A1 (en) * 2020-04-21 2023-10-05 Anovia Biosciences, Inc. Lox enzyme inhibiting methods and compositions
EP4173639A4 (en) 2020-06-26 2024-03-13 RaQualia Pharma Inc. METHOD FOR SELECTING A CANCER PATIENT FOR WHICH COMBINATION THERAPY OF A RETINOID AND A CANCER TREATMENT AGENT WILL BE EFFECTIVE, AND COMBINATION DRUG OF A RETINOID AND A CANCER TREATMENT AGENT
KR102608183B1 (ko) * 2021-03-11 2023-11-30 연세대학교 산학협력단 신규한 인돌라진 유도체 및 이를 포함하는 암의 예방 또는 치료용 조성물
KR102631074B1 (ko) * 2021-04-09 2024-01-30 연세대학교 산학협력단 신규한 인돌라진 유도체 및 이를 포함하는 섬유증의 예방 또는 치료용 조성물
JP2024540345A (ja) * 2021-10-28 2024-10-31 アノヴィア バイオサイエンシーズ インコーポレイテッド Ｌｏｘ酵素阻害方法及び組成物
US12233056B2 (en) 2022-04-06 2025-02-25 Syntara Limited Lysyl oxidase inhibitors for treating myeloid malignancies
GB202209624D0 (en) 2022-06-30 2022-08-17 Institute Of Cancer Res Royal Cancer Hospital Prodrugs
GB202209622D0 (en) 2022-06-30 2022-08-17 Institute Of Cancer Res Royal Cancer Hospital Compounds

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1015073A (en) 1911-06-19 1912-01-16 Ley P Rexford Knockdown brooder.
US1077406A (en) 1912-03-18 1913-11-04 Edward Hixon Apparatus for treating water.
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
IE56702B1 (en) 1982-12-01 1991-11-06 Usv Pharma Corp Antiinflammatory antiallergic compounds
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
NZ228068A (en) * 1988-02-25 1991-11-26 Merrell Dow Pharma Brominated or chlorinated allylamines and their pharmaceutical compositions
US5021456A (en) * 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5250532A (en) 1991-04-11 1993-10-05 Dowelanco 3,4,N-trisubstituted-4,5-dihydro-1H-pyrazole-1-carboxamides and their use as insecticides
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
US6956047B1 (en) 1995-06-06 2005-10-18 Pfizer Inc. Corticotropin releasing factor antagonists
US7067664B1 (en) 1995-06-06 2006-06-27 Pfizer Inc. Corticotropin releasing factor antagonists
US6632823B1 (en) 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
EA200200688A1 (ru) 2000-01-18 2003-02-27 Пфайзер Продактс Инк. Антагонисты фактора, высвобождающего кортикотропин
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20020147198A1 (en) 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
FI20030030A0 (fi) 2003-01-09 2003-01-09 Orion Corp Uusia yhdisteitä
CN1791395B (zh) 2003-05-19 2012-09-26 Irm责任有限公司 免疫抑制剂化合物及组合物
EP1715868A1 (en) 2004-01-29 2006-11-02 Pfizer Products Incorporated Combinations of an atypical antipsychotic and an aminomethylpyridyloxymethyl/benzisoxazole azabicyclic derivatives for treating cns disorders
ATE475640T1 (de) 2004-03-12 2010-08-15 Lilly Co Eli Antagonisten des opioidrezeptors
CA2557794A1 (en) 2004-03-15 2005-10-06 Eli Lilly And Company Opioid receptor antagonists
AU2005238386A1 (en) 2004-04-30 2005-11-10 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof as an MMP-13 inhibitor
US7507748B2 (en) 2004-07-22 2009-03-24 Amgen Inc. Substituted aryl-amine derivatives and methods of use
BRPI0515143A (pt) 2004-09-10 2008-07-08 Pfizer Prod Inc usos de derivados azabicìclicos de piridiloximetila e benzisoxazol para a preparação de uma composição farmacêutica para o tratamento dos distúrbios de humor
EP1791540A2 (en) 2004-09-10 2007-06-06 Pfizer Products Incorporated Methods of treating cognitive disorders using pyridyloxymethyl and benzisoxazole azabicyclic derivatives
WO2006052546A2 (en) 2004-11-04 2006-05-18 Neurogen Corporation Pyrazolylmethyl heteroaryl derivatives
DE102004056226A1 (de) * 2004-11-22 2006-05-24 Burchardt, Elmar Reinhold, Dr.Dr. Neuartige Inhibitoren der Lysyloxidase
WO2006083781A1 (en) 2005-01-31 2006-08-10 Merck & Co., Inc. Antidiabetic bicyclic compounds
AR055041A1 (es) 2005-03-23 2007-08-01 Merck Frosst Canada Ltd Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas.
EP1915369A4 (en) 2005-08-11 2010-09-08 Merck Frosst Canada Ltd NEW SUBSTITUTED 1,2,3-TRIAZOLYLMETHYLBENZOTHIOPHENE OR ENDOLE AND THEIR USE AS INHIBITORS OF LEUKOTRIENBIOSYNTHESIS
US7405302B2 (en) 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
ITMI20051943A1 (it) 2005-10-14 2007-04-15 Procos Spa Processo di risoluzione anantiomerica di 2-aminometil-pirrolidine 1-sostitute per ammidazione in presenza di lipasi
US20070225285A1 (en) 2005-11-04 2007-09-27 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US20070219206A1 (en) 2005-11-04 2007-09-20 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
CA2636043A1 (en) 2006-01-23 2007-08-02 Amira Pharmaceuticals, Inc. Tricyclic inhibitors of 5-lipoxygenase
GB0614579D0 (en) 2006-07-21 2006-08-30 Black James Foundation Pyrimidine derivatives
WO2008020799A1 (en) 2006-08-18 2008-02-21 Astrazeneca Ab Thienopyrimidin-4-one and thienopyridazin-7-one derivatives as mch rl antagonists
IL184627A0 (en) 2007-07-15 2008-12-29 Technion Res & Dev Foundation Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
CN105622756B (zh) 2007-08-02 2020-07-28 吉利德生物制剂公司 Lox和loxl2抑制剂及其应用
JP2013500974A (ja) 2009-07-28 2013-01-10 アナコール ファーマシューティカルズ，インコーポレイテッド 三置換ホウ素含有分子
EP2467162A4 (en) 2009-08-21 2013-10-02 Gilead Biologics Inc THERAPEUTIC PROCESSES AND RELATED COMPOSITIONS
SG183174A1 (en) 2010-02-04 2012-09-27 Gilead Biologics Inc Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
US9260417B2 (en) 2010-02-08 2016-02-16 Amitech Therapeutic Solutions, Inc. Therapeutic methods and compositions involving allosteric kinase inhibition
WO2011109799A1 (en) * 2010-03-05 2011-09-09 Karyopharm Therapeutics, Inc. Nuclear transport modulatiors and uses thereof
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
PE20140146A1 (es) * 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
TW201313721A (zh) * 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
CA2852936A1 (en) * 2011-10-20 2013-04-25 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
MX366308B (es) * 2012-04-25 2019-07-04 Raqualia Pharma Inc Derivados de amida como bloqueadores de ttx-s.
SG11201503065PA (en) 2012-10-30 2015-05-28 Gilead Sciences Inc Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2)
WO2014098098A1 (ja) 2012-12-18 2014-06-26 味の素株式会社 複素環アミド誘導体及びそれを含有する医薬
AU2015298491A1 (en) 2014-02-14 2016-09-01 The University Of British Columbia Modulators of caspase-6
US9051320B1 (en) 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
CN107922392B (zh) * 2015-02-15 2020-07-21 豪夫迈·罗氏有限公司 1-(杂)芳基磺酰基-(吡咯烷或哌啶)-2-甲酰胺衍生物及其用途
JP6800872B2 (ja) * 2015-03-06 2020-12-16 ファーマケア，インク． リシルオキシダーゼ様２阻害剤とその使用
EP3795568A1 (en) 2015-03-06 2021-03-24 Pharmakea, Inc. Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
MA46203A (fr) 2016-09-07 2019-07-17 Pharmakea Inc Utilisations d'un inhibiteur d'homologue 2 de lysyl-oxydase
JP7079772B2 (ja) 2016-09-07 2022-06-02 ファーマケア，インク． リシルオキシダーゼ様２阻害剤の結晶形態および製造方法

Also Published As

Publication number Publication date
EP3265456A1 (en) 2018-01-10
AU2016229268A1 (en) 2017-09-21
US10150732B2 (en) 2018-12-11
WO2016144703A1 (en) 2016-09-15
EP3795568A1 (en) 2021-03-24
CN107592861B (zh) 2021-06-08
BR112017019150B1 (pt) 2023-05-09
KR20170125897A (ko) 2017-11-15
PH12017501611A1 (en) 2018-03-05
MX2017011269A (es) 2018-01-12
ES2838977T3 (es) 2021-07-02
AU2016229268B2 (en) 2020-09-10
JP2018512381A (ja) 2018-05-17
CA2977947A1 (en) 2016-09-15
EP3265456A4 (en) 2018-07-18
EA034891B1 (ru) 2020-04-02
US11072585B2 (en) 2021-07-27
EA201791874A1 (ru) 2018-01-31
CN107592861A (zh) 2018-01-16
BR112017019150A2 (pt) 2018-07-31
EP3265456B1 (en) 2020-11-18
AU2020220225A1 (en) 2020-09-10
IL254236A0 (en) 2017-10-31
US20190119211A1 (en) 2019-04-25
SG11201707246YA (en) 2017-10-30
KR102594441B1 (ko) 2023-10-25
JP6697809B2 (ja) 2020-05-27
US20170369443A1 (en) 2017-12-28
US20200115341A1 (en) 2020-04-16
US10570094B2 (en) 2020-02-25

Similar Documents

Publication Publication Date Title
MX376835B (es) Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos.
MX386752B (es) Agonistas del receptor farnesoide x y usos de los mismos.
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
EA201990665A1 (ru) Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака
MX390120B (es) Moduladores de la somatostatina y usos de los mismos.
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
EP3735976A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
NI201600164A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
MX378273B (es) Compuestos activos hacia bromodominios.
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
PH12017501095A1 (en) Piperidine derivatives as hdac1/2 inhibitors
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
MX392182B (es) Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX378163B (es) Composiciones terapeuticas y nutricionales para trastornos gastrointestinales funcionales.
CL2018002848A1 (es) Formulaciones liquidas de fosfoplatino
WO2016144706A3 (en) Autotaxin inhibitor compounds and uses thereof
WO2016144704A3 (en) Heterocyclic autotaxin inhibitor compounds
HK1242692A1 (en) Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
PH12020500472A1 (en) Autotaxin inhibitor compounds

Legal Events

Date Code Title Description
FG Grant or registration